McDougle CJ, Goodman WK, Price LH. 1993. The pharmacotherapy of obsessive-compulsive disorder. Pharmacopsychiatry, 26(Suppl 1):24–9. McDougle CJ, Price LH, Goodman WK, et al. 1991. A controlled trial of lithium augmentation in ﬂuvoxamine-refractory obsessive-compulsive disorder:lack of efﬁcacy. J Clin Psychopharmacol, 11:175–84. Montgomery SA, Nil R, Durr-Pal N, et al. 2005. A 24 week randomized, double-blind, placebo-controlled study of escitalopram for the prevention of generalized social anxiety disorder. J Clin Psychiatry, 66:1270–8. Moritz S, Rufer M, Fricke S, et al. 2005. Quality of life in obsessive-compulsive disorder before and after treatment. Compr Psychiatry, 46:453–9. Mundo E, Guglielmo E, Bellodi L. 1998. Effect of adjuvant pindolol on the antiobsessional response to ﬂuvoxamine: a double-blind, placebo- controlled study. Int Clin Psychopharmacol, 13:219–24. Pallanti S, Hollander E, Bienstock C, et al. 2002. Treatment non-response in OCD: methodological issues and operational definitions. Int J Neuropsychopharmacol, 5:181–91. Phelps NJ, Cates ME. 2005. The role of venlafaxine in the treatment of obsessive-compulsive disorder. Ann Pharmacother, 39:136–40. Praharaj SK. 2004. Escitalopram treatment of transvestic fetishism: a case report. German J Psychiatry, 7:20–1. Sanchez C, Bergqvist PB, Brennum LT, et al. 2003. Escitalopram, the S-(+)-enantiomer of citalopram, is a selective serotonin reuptake inhibi- tor with potent effects in animal models predictive of antidepressant and anxiolytic activities. Psychopharmacology (Berl), 167:353–62. Escitalopram for OCD Sanchez C, Gruca P, Bien E, et al. 2003. R-citalopram counteracts the effect of escitalopram in a rat conditioned fear stress model of anxiety. Pharmacol Biochem Behav, 75:903–7. Simpson HB, Liebowitz MR, Foa EB, et al. 2004. Post-treatment effects of exposure therapy and clomipramine in obsessive-compulsive disorder. Depress Anxiety, 19:225–33. Skoog G, Skoog I. 1999. A 40-year follow-up of patients with obsessive- compulsive disorder. Arch Gen Psychiatry, 56:121–7. Starcevic V. 2005. Issues in the pharmacological treatment of anxiety disorders. Australas Psychiatry, 13:371–4. Stein DJ, Andersen EW, Tonnoir B, et al. 2007. Escitalopram in obsessive-compulsive disorder: a randomized, placebo-controlled, paroxetine-referenced, ﬁxed-dose, 24 week study. Curr Med Res Opin, 23:701–11. Storustovu S, Sanchez C, Porzgen P, et al. 2004. R-citalopram func- tionally antagonises escitalopram in vivo and in vitro: evidence for kinetic interaction at the serotonin transporter. Br J Pharmacol, 142:172–80. von Moltke LL, Greenblatt DJ, Giancarlo GM, et al. 2001. Escitalopram (S-citalopram) and its metabolites in vitro: cytochromes mediating biotransformation, inhibitory effects, and comparison to R-citalopram. Drug Metab Dispos, 29:1102–9. Neuropsychiatric Disease and Treatment 2007:3(4) 461